Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.603
Peer-review started: March 20, 2018
First decision: April 11, 2018
Revised: July 10, 2018
Accepted: July 15, 2018
Article in press: July 16, 2018
Published online: September 27, 2018
Core tip: As the surrogate biomarkers of intrahepatic viral replicative activity, hepatitis B surface antigen (HBsAg), hepatitis B core-related antigen (HbcrAg), and serum hepatitis B virus (HBV) RNA levels have been advocated as novel serum markers for treatment response in chronic hepatitis B. Currently, quantitative HBsAg has been widely used for predicting treatment response of chronic hepatitis B. HBcrAg can predict the risk of post-treatment reactivation of HBV as it is detectable in patients whose HBV DNA levels are undetectable or HBsAg loss is achieved. Serum HBV RNA may be useful in monitoring drug withdrawal, but clinical studies with large sample sizes remain necessary to further determine this capability.